A: Weight, waist, appetite, GI side effects, energy, protein intake, and training performance
alternative routes have unknown safety implications Efficacy : The dose-response relationship established in trials assumes subcutaneous delivery Tolerability : Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are dose-dependent and may be affected by altered absorption Patients with lower body mass index or those injecting in areas with less subcutaneous fat may be at higher risk of inadvertent intramuscular injection if proper technique is not followed
Avoid vigorous shaking, which can damage peptide chains
Pancreatitis history or significant gallbladder disease (requires careful assessment)
This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life